392 related articles for article (PubMed ID: 22927555)
1. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study.
Borer JS; Böhm M; Ford I; Komajda M; Tavazzi L; Sendon JL; Alings M; Lopez-de-Sa E; Swedberg K;
Eur Heart J; 2012 Nov; 33(22):2813-20. PubMed ID: 22927555
[TBL] [Abstract][Full Text] [Related]
2. Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients.
Rogers JK; Kielhorn A; Borer JS; Ford I; Pocock SJ
Curr Med Res Opin; 2015; 31(10):1903-9. PubMed ID: 26361063
[TBL] [Abstract][Full Text] [Related]
3. Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT.
Komajda M; Tavazzi L; Swedberg K; Böhm M; Borer JS; Moyne A; Ford I;
Eur J Heart Fail; 2016 Sep; 18(9):1182-9. PubMed ID: 27210035
[TBL] [Abstract][Full Text] [Related]
4. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
5. Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT.
Böhm M; Lloyd SM; Ford I; Borer JS; Ewen S; Laufs U; Mahfoud F; Lopez-Sendon J; Ponikowski P; Tavazzi L; Swedberg K; Komajda M
Eur J Heart Fail; 2016 Jun; 18(6):672-83. PubMed ID: 26952245
[TBL] [Abstract][Full Text] [Related]
6. Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease.
Borer JS; Deedwania PC; Kim JB; Böhm M
Am J Cardiol; 2016 Dec; 118(12):1948-1953. PubMed ID: 27780557
[TBL] [Abstract][Full Text] [Related]
7. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
[TBL] [Abstract][Full Text] [Related]
10. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
[TBL] [Abstract][Full Text] [Related]
11. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
[TBL] [Abstract][Full Text] [Related]
12. Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT.
Böhm M; Komajda M; Borer JS; Ford I; Maack C; Tavazzi L; Moyne A; Swedberg K;
Eur J Heart Fail; 2018 Feb; 20(2):373-381. PubMed ID: 29027329
[TBL] [Abstract][Full Text] [Related]
13. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
[TBL] [Abstract][Full Text] [Related]
14. Time to benefit of heart rate reduction with ivabradine in patients with heart failure and reduced ejection fraction.
Böhm M; Abdin A; Slawik J; Mahfoud F; Borer J; Ford I; Swedberg K; Tavazzi L; Batailler C; Komajda M
Eur J Heart Fail; 2023 Aug; 25(8):1429-1435. PubMed ID: 37092340
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
Komajda M; Tavazzi L; Francq BG; Böhm M; Borer JS; Ford I; Swedberg K;
Eur J Heart Fail; 2015 Dec; 17(12):1294-301. PubMed ID: 26377342
[TBL] [Abstract][Full Text] [Related]
16. Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine.
Pereira-Barretto AC
Am J Cardiovasc Drugs; 2016 Apr; 16(2):93-101. PubMed ID: 26817946
[TBL] [Abstract][Full Text] [Related]
17. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
Böhm M; Robertson M; Borer J; Ford I; Komajda M; Mahfoud F; Ewen S; Swedberg K; Tavazzi L
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873681
[TBL] [Abstract][Full Text] [Related]
18. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
19. Risk following hospitalization in stable chronic systolic heart failure.
Abrahamsson P; Swedberg K; Borer JS; Böhm M; Kober L; Komajda M; Lloyd SM; Metra M; Tavazzi L; Ford I
Eur J Heart Fail; 2013 Aug; 15(8):885-91. PubMed ID: 23460732
[TBL] [Abstract][Full Text] [Related]
20. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial.
Bocchi EA; Rassi S; Guimarães GV;
ESC Heart Fail; 2018 Jun; 5(3):249-256. PubMed ID: 29266804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
